T1	intervention 0 52	Autologous bone marrow stromal cells transplantation
T2	intervention-participants 395 402	Fifteen
T3	eligibility 403 500	women with lymphedema, who had undergone breast cancer surgery and/no radiotherapy 5 years before
T5	control 630 633	CDT
T7	outcome 892 929	average decrease in lymphedema volume
T8	iv-cont-mean 933 938	730.7
T9	iv-cont-mean 940 945	887.9
T10	iv-cont-mean 950 958	958.6 ml
T11	cv-cont-mean 981 986	714.8
T12	cv-cont-mean 988 993	657.9
T13	cv-cont-mean 998 1006	571.3 ml
T14	outcome 1024 1048	after 1, 3 and 12 months
T16	iv-cont-mean 1208 1212	64.6
T17	iv-cont-mean 1214 1218	78.5
T18	iv-cont-mean 1223 1228	81.0%
T19	cv-cont-mean 1251 1255	67.2
T20	cv-cont-mean 1257 1261	60.4
T21	cv-cont-mean 1266 1271	54.5%
T22	outcome 1289 1313	after 1, 3 and 12 months
T23	outcome 1371 1375	pain
T24	iv-cont-mean 1448 1451	3.4
T25	cv-cont-mean 1474 1477	4.0
T26	outcome 1500 1513	average score
T27	iv-cont-mean 1529 1532	1.6
T28	iv-cont-mean 1534 1537	0.8
T29	iv-cont-mean 1542 1545	0.6
T30	cv-cont-mean 1571 1574	1.2
T31	cv-cont-mean 1576 1579	1.7
T32	cv-cont-mean 1584 1587	1.6
T33	outcome 1601 1625	after 1, 3 and 12 months
T35	iv-cont-mean 1115 1120	28.6%
T36	cv-cont-mean 1143 1148	26.8%
T38	iv-cont-mean 809 818	1166.2 ml
T39	cv-cont-mean 837 846	1091.0 ml
T6	outcome 731 747	Before treatment
T34	outcome 762 785	average volume of edema
T37	outcome 1064 1080	Before treatment
T40	outcome 1086 1110	percentage of lymphedema
T41	outcome 1167 1182	After treatment
T4	control-participants 570 572	35
